PL3612207T3 - Warianty coversin niewykazujące wiązania c5 - Google Patents

Warianty coversin niewykazujące wiązania c5

Info

Publication number
PL3612207T3
PL3612207T3 PL18719169.7T PL18719169T PL3612207T3 PL 3612207 T3 PL3612207 T3 PL 3612207T3 PL 18719169 T PL18719169 T PL 18719169T PL 3612207 T3 PL3612207 T3 PL 3612207T3
Authority
PL
Poland
Prior art keywords
binding
variants lacking
coversin
coversin variants
lacking
Prior art date
Application number
PL18719169.7T
Other languages
English (en)
Polish (pl)
Inventor
Miles Andrew Nunn
Original Assignee
Volution Immuno Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volution Immuno Pharmaceuticals Sa filed Critical Volution Immuno Pharmaceuticals Sa
Publication of PL3612207T3 publication Critical patent/PL3612207T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PL18719169.7T 2017-04-21 2018-04-20 Warianty coversin niewykazujące wiązania c5 PL3612207T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1706406.4A GB201706406D0 (en) 2017-04-21 2017-04-21 Method of treatment
PCT/EP2018/060240 WO2018193121A1 (en) 2017-04-21 2018-04-20 Coversin variants lacking c5 binding

Publications (1)

Publication Number Publication Date
PL3612207T3 true PL3612207T3 (pl) 2024-09-23

Family

ID=58795719

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18719169.7T PL3612207T3 (pl) 2017-04-21 2018-04-20 Warianty coversin niewykazujące wiązania c5

Country Status (12)

Country Link
US (2) US11214602B2 (enExample)
EP (1) EP3612207B1 (enExample)
JP (1) JP7183180B2 (enExample)
KR (1) KR102630702B1 (enExample)
CN (1) CN110799207B (enExample)
AU (1) AU2018253961B2 (enExample)
CA (1) CA3060336A1 (enExample)
ES (1) ES2980279T3 (enExample)
GB (1) GB201706406D0 (enExample)
IL (1) IL269856B2 (enExample)
PL (1) PL3612207T3 (enExample)
WO (1) WO2018193121A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060331A1 (en) * 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of cicatrising eye inflammatory disorders
EP3612208B1 (en) 2017-04-21 2023-04-05 Volution Immuno Pharmaceuticals SA Coversin for the treatment of autoimmune blistering diseases
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
AU2019468121A1 (en) 2019-09-27 2022-05-12 Volution Immuno Pharmaceuticals Sa Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001241156A1 (en) * 2000-03-21 2001-10-03 Yamanouchi Pharmaceutical Co..Ltd. Novel leukotriene b4 receptor
EP1575496A4 (en) * 2002-04-05 2008-01-23 Univ Utah Res Found COLON TUMOR SPECIFIC BINDING PEPTIDES
MXPA05012880A (es) 2003-06-02 2006-02-22 Evolutec Ltd Inhibidores de complemento.
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
BRPI0809105A2 (pt) 2007-03-22 2019-09-10 Novartis Ag antígenos c5 e uso destes
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) * 2009-04-20 2009-06-03 Natural Environment Res Council Composition
EP3524258B1 (en) 2011-06-22 2025-10-01 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
GB201410031D0 (en) 2014-06-05 2014-07-16 Isis Innovation Polypeptides and uses thereof
CA2988313A1 (en) * 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
CA3060331A1 (en) 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of cicatrising eye inflammatory disorders
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
EP3612208B1 (en) 2017-04-21 2023-04-05 Volution Immuno Pharmaceuticals SA Coversin for the treatment of autoimmune blistering diseases

Also Published As

Publication number Publication date
ES2980279T3 (es) 2024-09-30
IL269856B2 (en) 2024-09-01
US20230002456A1 (en) 2023-01-05
JP7183180B2 (ja) 2022-12-05
AU2018253961B2 (en) 2022-06-02
WO2018193121A1 (en) 2018-10-25
CA3060336A1 (en) 2018-10-25
KR102630702B1 (ko) 2024-01-29
AU2018253961A1 (en) 2019-10-31
EP3612207C0 (en) 2024-04-10
US20200385434A1 (en) 2020-12-10
CN110799207B (zh) 2024-05-03
EP3612207A1 (en) 2020-02-26
IL269856B1 (en) 2024-05-01
US11214602B2 (en) 2022-01-04
KR20190141163A (ko) 2019-12-23
CN110799207A (zh) 2020-02-14
EP3612207B1 (en) 2024-04-10
GB201706406D0 (en) 2017-06-07
JP2020517260A (ja) 2020-06-18
IL269856A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
IL272643A (en) Binders
ZA201804317B (en) Altered april binding antibodies
IL269856A (en) Coversin variants lack C5 ligands
SG10202113337YA (en) Aggrecan binding immunoglobulins
GB201715123D0 (en) FlyLogix Big Book
IL268288A (en) Binders
PL3630847T3 (pl) Immunoglobuliny wiążące adamts
GB201810211D0 (en) Foregin title
PT3456736T (pt) Variantes de anticorpos
IL269477A (en) Polypeptides that bind to IL-1R-1
ZA202001830B (en) Antibody variants
GB201704620D0 (en) Combinations
IL272951A (en) antibody variants
GB201718538D0 (en) u
HRP20200167T1 (hr) Nadogradnja implantata
GB201715149D0 (en) IL-ß binding antibody
GB201713296D0 (en) Binding agents
GB201713298D0 (en) Binding agents
GB201701351D0 (en) Binding agents
HK40010439A (en) Binding agents
IL256197A (en) Binding folder
GB201618186D0 (en) Binding members
GB201716492D0 (en) Disclosure
GB201715938D0 (en) Disclosure
GB201715756D0 (en) Disclosure